Designing new treatments for heart rhythm disorders using natural peptides
Rational Design from Cryo-EM Structures of High-Affinity Ryanodine Receptor Ligands Based on Natural Peptides
This study is looking at how certain proteins in heart cells can cause dangerous heart rhythm problems in kids, and it aims to create new treatments that could help fix these issues and keep their hearts beating normally.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10881926 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins in heart cells, known as ryanodine receptors, contribute to dangerous heart rhythm disorders in children. By studying the structure of these receptors, the team aims to create new high-affinity ligands, which are molecules that can bind to these receptors and potentially correct their malfunction. The approach involves using advanced imaging techniques to visualize the receptors and designing peptides that can effectively interact with them to restore normal function. This could lead to new therapies for conditions like catecholaminergic polymorphic ventricular tachycardia (CPVT), which can cause life-threatening arrhythmias.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who have been diagnosed with arrhythmogenic conditions, particularly those related to ryanodine receptor dysfunction.
Not a fit: Patients with heart rhythm disorders not linked to ryanodine receptor dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly improve heart health and reduce the risk of sudden cardiac events in affected children.
How similar studies have performed: Previous research has shown promise in targeting ryanodine receptors with peptides, indicating that this approach could be effective.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Valdivia, Hector H — University of Wisconsin-Madison
- Study coordinator: Valdivia, Hector H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.